Derived From Bacteria Patents (Class 435/220)
  • Patent number: 10648045
    Abstract: Chimeric clostridial neurotoxins in which the activation loop has been replaced by an activation loop from a different subtype within the same serotype. Methods of producing, activating, and using such neurotoxins. Compositions comprising such neurotoxins. Polynucleotides, vectors and cells for expressing such neurotoxins.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: May 12, 2020
    Assignee: IPSEN BIOPHARM LIMITED
    Inventors: Daniel Kwan, David Burgin, Stephen Gavin Hackett
  • Patent number: 10538722
    Abstract: The present invention relates to metalloproteases and the use thereof in cleaning processes, such as laundry and dish wash. The invention also relates to detergent compositions and cleaning compositions comprising a metalloprotease.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: January 21, 2020
    Assignee: NOVOZYMES A/S
    Inventors: Morten Gjermansen, Peter R. Oestergaard, Jeannette Bjerre
  • Patent number: 10501731
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: December 10, 2019
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Patent number: 10155061
    Abstract: The present invention is directed to topical enzymatic wound debriding compositions with enhanced enzymatic activity. These compositions comprise a dispersed phase comprising at least one proteolytic enzyme and at least one hydrophilic polyol; and a continuous phase comprising a hydrophobic base.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: December 18, 2018
    Assignee: Smith & Nephew, Inc.
    Inventors: Lei Shi, Aleksa Jovanovic, Duncan Aust
  • Patent number: 9938514
    Abstract: The present specification discloses expression constructs comprising single-chain proteins comprising a di-chain loop region comprising an exogenous protease cleavage site and a protease that can cleave the exogenous protease cleavage site located within the di-chain loop, cell compositions comprising such expression construct, and intracellular methods of converting the single-chain protein into its di-chain form.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: April 10, 2018
    Assignee: Allergan, Inc.
    Inventors: Sanjiv Ghanshani, Linh Q. Le, Yi Liu, Lance E. Steward
  • Patent number: 9856466
    Abstract: The present invention provides serine protease variants, more specifically subtilisin variants produced there from. Specifically, the present invention provides serine protease variants, more specifically subtilisin variants having one or more substitutions as compared to a reference serine protease. In addition, the present invention provides compositions comprising these serine protease variants, more specifically subtilisin variants. In some embodiments, the present invention provides cleaning compositions comprising at least one of these serine protease variants, more specifically subtilisin variants.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: January 2, 2018
    Assignee: DANISCO US INC.
    Inventors: Neelam S. Amin, Katherine Augustyn, Joshua R. Basler, Luis G. Cascao-Pereira, Katherine D. Collier, Edward M. Concar, David A. Estell, James T. Kellis, Jr., Euan John Magennis, Alexander Pisarchik, Ayrookaran J. Poulose, Philip Frank Souter, Glenn Steven Ward, Jian Yao
  • Patent number: 9850476
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: December 26, 2017
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Patent number: 9757435
    Abstract: The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: September 12, 2017
    Assignee: ENDO GLOBAL VENTURES
    Inventor: Wayne K. Herber
  • Patent number: 9694100
    Abstract: The present invention is directed to topical enzymatic wound debriding compositions with enhanced enzymatic activity. These compositions comprise a dispersed phase comprising at least one proteolytic enzyme and at least one hydrophilic polyol; and a continuous phase comprising a hydrophobic base.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: July 4, 2017
    Assignee: Smith & Nephew, Inc.
    Inventors: Lei Shi, Aleksa Jovanovic, Duncan Aust
  • Patent number: 9528107
    Abstract: Methods are provided for reducing the complexity of a population of nucleic acids prior to performing an analysis of the nucleic acids, e.g., sequence analysis. The methods result in a subset of the initial population enriched for a target region, which is typically located within one or more target fragments. The methods are particularly useful for analyzing populations having a high degree of complexity, e.g., chromosomal-derived DNA, whole genomic DNA, or mRNA populations.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: December 27, 2016
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Thang Tat Pham, Yu-Chih Tsai, Jonas Korlach, Tyson A. Clark, Stephen Turner
  • Patent number: 9434934
    Abstract: A fusion gene encoding M. taiwanensis WR-220 keratinase is disclosed. The fusion comprises: (a) a first DNA sequence encoding a protein secretion signal peptide, located at the N-terminus of the fusion gene; (b) a second DNA sequence encoding an inhibitory domain of M. taiwanensis WR-220 keratinase, linked in translation frame with the first DNA sequence; and (c) a third DNA sequence encoding a catalytic domain of M. taiwanensis WR-220 keratinase, linked in translation frame with the second DNA sequence, wherein the fusion gene is a non-naturally occurring chimeric DNA. Also disclosed are a method for preparation of the catalytic domain of M. taiwanensis WR-220 keratinase, and use of the M. taiwanensis WR-220 keratinase.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: September 6, 2016
    Assignee: ACADEMIA SINICA
    Inventors: Meng-Chiao Ho, Shih-Hsiung Wu, Wan-Ling Wu
  • Patent number: 9404164
    Abstract: The present invention is related to a fungal serine protease enzyme, which said enzyme has serine protease activity and comprises an amino acid sequence of Malbranchea ALKO4122 mature protease as defined in SEQ ID NO:18 or an amino acid sequence having at least 66% identity to the amino acid sequence of SEQ ID NO:18. Also disclosed is an isolated nucleic acid molecule, comprising a polynucleotide sequence which encodes a fungal serine protease enzyme, nucleic acid sequences encoding said protease, a host cell and a process of producing a polypeptide having serine protease activity. Said protease is useful as an enzyme preparation applicable in detergent compositions and for treating fibers, wool, hair, leather, or silk, for treating food or feed, or for any applications involving modification, degradation or removal of proteinaceous material.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: August 2, 2016
    Assignee: AB Enzymes Oy
    Inventors: Leena Valtakari, Kari Juntunen, Marja Paloheimo, Pentti Ojapalo
  • Patent number: 9297003
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: March 29, 2016
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Patent number: 9284545
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: March 15, 2016
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Patent number: 9279116
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: March 8, 2016
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Patent number: 9072819
    Abstract: The present invention relates in one aspect to the use of a matrix gel comprising chondrocytes or progenitor cells thereof in a density below that of natural cartilage as a cartilage repair implant wherein said cells exhibit increases production of extracellular matrix material.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: July 7, 2015
    Assignee: CELLCOTEC B.V.
    Inventors: Jeanine Anna Alphonse Hendriks, Jens Uwe Riesle
  • Publication number: 20150147313
    Abstract: The present invention refers to a culture medium and a process for producing proteases with collagenolytic and gelatinolytic activity by bacteria of the genus Clostridium. Particularly, the present invention refers to an animal product-free culture medium for C. histolyticum, characterized by comprising non-animal origin peptones, preferably vegetable peptones, yeast extract and the amino acids cysteine and arginine. The present invention also refers to a process for producing Clostridium histolyticum liquid culture supernatant comprising one or more proteases with collagenolytic and gelatinolytic activity, and pharmaceutical composition comprising as active ingredient the supernatant or the supernatant optionality purified.
    Type: Application
    Filed: May 29, 2013
    Publication date: May 28, 2015
    Inventors: Marcos Castanheira Alegria, Lucidio Cristoväo Fardelone, Marina Baiochi Riboldi Delalana, Josef Ernst Thiemann, Spartaco Astolfi Filho, Roberto Carlos Debom Moreira, Ogari de Castro Pacheco
  • Patent number: 9034322
    Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: May 19, 2015
    Assignee: The Rockefeller University
    Inventors: Vincent A. Fischetti, Jonathan Schmitz, Daniel Gilmer, Chad Euler
  • Publication number: 20150132749
    Abstract: The invention generally relates to methods and kits for isolating nucleic acids from an organism. In certain embodiments, methods of the invention involve contacting a plurality of lytic enzymes to an organism, thereby lysing a cell wall of the organism to release the nucleic acid, and introducing at least one agent to separate the nucleic acid from the lysed cells, thereby isolating the nucleic acid.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 14, 2015
    Inventor: John Kevin Henkhaus
  • Publication number: 20150125925
    Abstract: The present invention provides consumer products comprising a serine protease variant, more specifically subtilisin variants produced there from. Specifically, the present invention provides consumer products comprising a serine protease variant, more specifically a subtilisin variant having one or more substitutions as compared to a reference serine protease. In addition, the present invention provides methods of making such compositions and methods of treating surfaces, particularly fabric surfaces comprising contacting a surface with an aqueous liquor comprising a serine protease variant, more specifically subtilisin variants and an adjunct material.
    Type: Application
    Filed: November 5, 2013
    Publication date: May 7, 2015
    Applicant: The Procter & Gamble Company
    Inventors: Philip Frank SOUTER, Euan John MAGENNIS, Glenn Steven WARD, Neelam S. AMIN, Katherine AUGUSTYN, Joshua R. BASLER, Luis Gustavo CASCAO-PEREIRA, Katherine D. COLLIER, Edward M. CONCAR, David A. ESTELL, James T. KELLIS, JR., Alexander PISARCHIK, Ayrookaran Joseph POULOSE, Jian YAO
  • Publication number: 20150118212
    Abstract: The present invention relates to the development of new derivatives of a bacterial plasminogen activator, Staphylokinase (SAK), having one or more amino acid residues with single or multiple cysteines at the amino and/or carboxy terminal ends and their conjugation with PEG (Polyethylene Glycol), resulting in new Staphylokinase derivatives that display altered oligomeric states, enhanced thermal and protease stability and extended plasma half-life. Also included is the cloning and expression in a suitable bacterial host; purification of Staphylokinase derivatives to homogeneity and their chemical modification by integrating a PEG molecule to create new biologically active Staphylokinases having higher protein stability and improved in vivo plasma half life, that may enhance the clinical potential of Staphylokinase in thrombolytic therapy for the treatment of cardiovascular diseases.
    Type: Application
    Filed: March 12, 2014
    Publication date: April 30, 2015
    Inventors: SATISH SINGH, Kanak Lata Dikshit
  • Publication number: 20150110830
    Abstract: Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein. The detoxified variants may be further modified to have increased solubility as compared to the native AcfD (orf3526) protein.
    Type: Application
    Filed: October 27, 2014
    Publication date: April 23, 2015
    Inventors: Laura SERINO, Maria Rita FONTANA, Danilo GOMES MORIEL
  • Patent number: 8999641
    Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors with additional functional domains. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: April 7, 2015
    Assignees: The Broad Institute Inc., Maassachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng Zhang, Le Cong, Randall Jeffrey Platt, Neville Espi Sanjana
  • Patent number: 8993233
    Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors with additional functional domains. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: March 31, 2015
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng Zhang, Le Cong, Randall Jeffrey Platt, Neville Espi Sanjana, Fei Ran
  • Publication number: 20150072380
    Abstract: The present invention relates to the identification of novel nucleic acid sequences, designated herein as 7p, 8k, 7E, 9G, 8Q and 203, in a host cell which effect protein production. The present invention also provides host cells having a mutation or deletion of part or all of the gene encoding 7p, 8k, 7E, 9G, 8Q and 203, which are presented in FIG. 1, and are SEQ ID NOS.: 1-6, respectively. The present invention also provides host cells further comprising a nucleic acid encoding a desired heterologous protein such as an enzyme.
    Type: Application
    Filed: September 23, 2014
    Publication date: March 12, 2015
    Applicant: DANISCO US INC.
    Inventors: Elizabeth A. Bodie, Steve Kim
  • Publication number: 20150072913
    Abstract: The present invention provides novel Micrococcineae spp serine proteases having multiple substitutions. In particular, the present invention provides serine proteases having multiple substitutions, DNA encoding these proteases, vectors comprising the DNA encoding the proteases, host cells transformed with the vector DNA, and enzymes produced by the host cells. The present invention also provides cleaning compositions (e.g., detergent compositions), animal feed compositions, and textile and leather processing compositions comprising these serine protease variants. In particularly preferred embodiments, the present invention provides mutant (i.e., variant) proteases derived from the wild-type proteases described herein. These variant proteases also find use in numerous applications.
    Type: Application
    Filed: September 11, 2014
    Publication date: March 12, 2015
    Applicant: DANISCO US INC.
    Inventors: Wolfgang Aehle, David A. Estell, Ronaldus W.J. Hommes, Brian E. Jones, Marc Kolkman, Chris Leeflang, Hiroshi Oh, Ayrookaran J. Poulose, Andrew Shaw, Wilhelmus A.H. Van der Kley, Leonardus P.M. Van Marrewijk
  • Publication number: 20150056179
    Abstract: The present invention claims a novel process for the production and purification of microbial collagenase (Microbial Collagenase EC 3.4.24.3) produced by the non-pathogenic aerobic bacterium Vibrio alginolyticus chemovar. iophagus (NCIMB Number: 1 1038, synonym LMG 3418, hereinafter called Vibrio alginolyticus), which said process provides high production levels of collagenase with a stable, reproducible, cheap fermentation process. The collagenase produced from Vibrio alginolyticus according to the process described herein also presents a specific activity superior to that of other microbial collagenases, is stable in aqueous solution, and can be frozen without significant damage.
    Type: Application
    Filed: April 17, 2013
    Publication date: February 26, 2015
    Applicant: FIDIA FARMACEUTICI S.P.A.
    Inventors: Susanna Vaccaro, Michele Caputo, Christian Cuppari, Giovanni Gennari
  • Patent number: 8945839
    Abstract: The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: February 3, 2015
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology
    Inventor: Feng Zhang
  • Publication number: 20150030584
    Abstract: The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum. The protein binds specifically to nerve cells with a higher affinity as the native neurotoxin. The invention also relates to a method for the production of transport protein, the nucleic acids coding for the transport protein, the transport protein containing pharmaceutical and cosmetic compositions and use thereof.
    Type: Application
    Filed: August 5, 2014
    Publication date: January 29, 2015
    Applicant: SYNTAXIN LIMITED
    Inventor: Andreas Rummel
  • Publication number: 20150031563
    Abstract: The disclosure provides methods for detecting the concurrent presence of at least two targets within a biological sample. The method includes contacting said biological sample with a first binding agent, said first binding agent operably linked to a first sortase molecule, wherein said first binding agent specifically binds to a first target; contacting said biological sample with a second binding agent, said second binding agent operably linked to a first sortase recognition sequence peptide, wherein said second binding agent specifically binds to a second target; adding a sortase substrate under conditions where a first sortase-mediated ligation of the sortase substrate to the first sortase recognition sequence will produce a ligation product, and detecting the ligation product, wherein detection of said ligation product indicates the concurrent presence of the first target and the second target in the biological sample. Also disclosed are kits comprising reagents for performing the methods as claimed.
    Type: Application
    Filed: July 27, 2012
    Publication date: January 29, 2015
    Inventors: Khanh Duc Huynh, Wan Cheung Cheung, Roberto Polakiewicz
  • Patent number: 8932814
    Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: January 13, 2015
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Le Cong, Feng Zhang
  • Publication number: 20140377248
    Abstract: This invention relates to a novel method for producing di-chain proteins for use in humans from single-chain precursors, including di-chain clostridial neurotoxins. The method comprises the step of expressing a nucleic acid sequence encoding a single-chain precursor comprising a thrombin-cleavage site and the step of cleaving the single-chain precursor with a human factor Xa or a human thrombin, particularly a human thrombin drug product authorized for human therapeutic use. The invention further relates to novel di-chain clostridial neurotoxins and nucleic acid sequences encoding such novel di-chain clostridial neurotoxins.
    Type: Application
    Filed: December 21, 2012
    Publication date: December 25, 2014
    Inventors: Swen Grein, Kerstin Hoelscher, Annett Eylenstein
  • Patent number: 8906662
    Abstract: Provided are compositions and methods for treating inflammation due to an immune response. Non-limiting example compositions include class-2 SPATE proteins that are capable of cleaving proteins involved in an inflammatory immune response in a patient. Example compositions include at least one mucin-cleaving class-2 SPATE protein. Further example compositions include protein involved in intestinal colonization (Pic). Non-limiting example methods include methods of decreasing inflammation in a patient having inflammation and methods of perturbing immune response in a patient having a disease or condition in which an active immune response is attributable to a cause of the disease or condition, by administering to the patient a composition including at least one class-2 SPATE protein capable of cleaving proteins involved in an inflammatory immune response.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: December 9, 2014
    Assignee: University of Maryland, Baltimore
    Inventors: James Nataro, Fernando Ruiz-Perez
  • Publication number: 20140356345
    Abstract: The invention relates to a new family of proteolytic enzymes having the ability to hydrolize at a p H between 3 and 8 gluten olygopeptides which are resistant to cleavage by gastric and pancreatic enzymes and whose presence in the intestinal lumen results in toxic effects. The enzymes have been identified as endopeptidases of the S8/S53 family and are produced by an Actinoallomurus strain. The object of the invention includes also methods for producing enzymes composition comprising the endopeptidases by cultivation of native Actinoallomurus strains, mutants thereof, or recombinant host cells comprising nucleic acids codifying for the endopeptidases. Said nucleic acids constitute a further object of the invention.
    Type: Application
    Filed: November 5, 2012
    Publication date: December 4, 2014
    Applicant: Fondazione Istituto Insubrico di Ricerca Per La Vita
    Inventors: Linda Cavaletti, Lucia Carrano, Monica Abbondi, Mara Brunati, Anna Taravella
  • Patent number: 8889356
    Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: November 18, 2014
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology
    Inventor: Feng Zhang
  • Publication number: 20140335595
    Abstract: The invention provides novel biologically pure cultures of microorganisms high in protease activity and capable of decomposing proteins recalcitrant to proteolysis as contained in garbage, waste water, organic waste liquids, industrial wastes and the like, a protease produced by such microorganisms and capable of decomposing proteins recalcitrant to proteolysis, and a method of utilizing the same. The novel culture is of a soil-derived microorganism belonging to Streptomyces sp., or a strain derived therefrom, which produces a protease capable of efficiently decomposing proteins recalcitrant to proteolysis as contained in waste water, organic waste liquids, industrial wastes and so forth.
    Type: Application
    Filed: June 5, 2014
    Publication date: November 13, 2014
    Inventors: Hiroyasu DOI, Naoko KINOSHITA, Tatsuzo OKA, Zhao HUI
  • Patent number: 8883444
    Abstract: The invention relates to a method for synthesizing a peptide by enzymatically preparing an ester or thioester from (i) an N-terminal protected amino acid or an N-terminal protected peptide where either can have a protected C-terminal ester group and (ii) an alcohol represented by the formula HO—CX2—Z or a thiol represented by the formula HS—CX2—Z, each X independently representing a halogen atom or a hydrogen atom; and Z represents an electron withdrawing group comprising at least one sp3-hybridized carbon comprising at least two substituents comprising a heteroatom directly attached to the at least one sp3-hybridized carbon or at least one sp2-hybridized carbon comprising one or two substituents comprising a heteroatom directly attached to the at least one sp2-hybridized carbon, and enzymatically coupling the prepared ester or thioester with an optionally C-terminal protected amino acid or with an optionally C-terminal protected peptide in a medium comprising 2 wt. % water or less.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: November 11, 2014
    Assignee: Enzypep B.V.
    Inventors: Peter Jan Leonard Mario Quaedflieg, Timo Nuijens, Claudia Cusan, Catharina Hubertina Maria Schepers
  • Patent number: 8871445
    Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: October 28, 2014
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Le Cong, Feng Zhang
  • Publication number: 20140314716
    Abstract: The invention relates to a Bacillus anthracis (B. anthracis) in which more than one secreted protease is inactivated by genetic modification. Such a protease-deficient B. anthracis has an improved ability to produce recombinant secreted proteins compared to other bacteria, particularly other Bacillus. Improvements include production of intact (i.e., mature full-length) proteins, often at high yield. The disclosure provides a B. anthracis that comprises a genetic modification that inactivates a protease of the M4 family of metallopro teases and a genetic modification that inactivates a protease of the M6 family of metalloproteases. Also provided is a modified B. anthracis comprising such genetic modification transformed with a recombinant molecule encoding a product, as well as methods to prepare and use such B. anthracis.
    Type: Application
    Filed: August 2, 2012
    Publication date: October 23, 2014
    Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SEC, OF DEPT OF HEALTH AND HUMAN SERVICES
    Inventors: Andrei P. Pomerantsev, Stephen H. Leppla
  • Patent number: 8865406
    Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are compositions and methods related to components of a CRISPR complex particularly comprising a Cas ortholog enzyme.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: October 21, 2014
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology
    Inventors: Feng Zhang, Fei Ran
  • Publication number: 20140308266
    Abstract: The present invention is concerned with modified neurotoxins. Specifically, it relates to a modified biologically active neurotoxin polypeptide comprising at least one poly-Glycine domain. Also contemplated is a polynucleotide encoding the modified neurotoxin polypeptide having a poly-Glycine domain fused to the N-terminus, to the C-terminus or to both of the heavy and/or light chain of the mature neurotoxin polypeptide, vector comprising it and a host cell comprising such a polynucleotide or a vector. Moreover, envisaged are the aforementioned compounds for use as a medicament for treating various diseases.
    Type: Application
    Filed: November 8, 2012
    Publication date: October 16, 2014
    Inventor: Karl-Heinz Eisele
  • Publication number: 20140308267
    Abstract: The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a neurotoxin polypeptide exhibiting a reduced duration of the biological effect in a subject, wherein said polypeptide comprises at least one E3 ligase recognition motif in the light chain, wherein said E3 ligase recognition motif is preferably a binding motif for the E3 ligase MDM2. The invention further pertains to polypeptides encoded by the polynucleotide of the invention as well as polypeptides comprising one or more amino acid substitutions. Further encompassed by the present invention are vectors and host cells comprising the said polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising said polynucleotides and polypeptides, as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments.
    Type: Application
    Filed: November 8, 2012
    Publication date: October 16, 2014
    Inventors: Michael Schmidt, Jurge Frevert, Fred Hofmann, Gerhard Groer
  • Publication number: 20140302004
    Abstract: Multi-drug resistant superbugs are a persistent problem in modern health care. This invention provides an antimicrobial endolysin-Lysostaphin triple fusion protein, comprising (1) an endolysin CHAP endopeptidase domain, (2) an endolysin amidase domain, and (3) a Lysostaphin glycyl-glycine endopeptidase domain. The domains are derived from two proteins that show antimicrobial synergy when used in combination. The protein has specificity and exolytic activity for the peptidoglycan cell wall of untreated, live Staphylococcus aureus from many growth phases i.e. stationary, logarithmic and biofilm growth. The recombinant triple fusion protein comprising the three functional antimicrobial domains is designed to be refractory to resistance development.
    Type: Application
    Filed: March 18, 2013
    Publication date: October 9, 2014
    Applicant: The United Sates of America, as represented by the Secretary of Agriculture
    Inventor: The United Sates of America, as represented by the Secretary of Agriculture
  • Publication number: 20140302006
    Abstract: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalised and inhibits secretion from said tumour cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.
    Type: Application
    Filed: April 11, 2014
    Publication date: October 9, 2014
    Applicant: Syntaxin Limited
    Inventors: Steven JOHNSTONE, Philip MARKS, Keith FOSTER
  • Patent number: 8841111
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: September 23, 2014
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Patent number: 8841110
    Abstract: Chromatographic processes and systems for purifying a botulinum toxin from an APF fermentation medium.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: September 23, 2014
    Assignee: Allergan, Inc.
    Inventors: Hui Xiang, Mingjiang Luo, Ping Wang, Stephen Donovan
  • Publication number: 20140255550
    Abstract: The invention relates to a novel 3D structure encoding a Nocardiopsis protease, as well as to variants of parent protease homologous to Nocardiopsis proteases, preferably of improved thermostability and/or with an amended temperature activity profile. The invention also relates to DNA sequences encoding such variants, their production in a recombinant host cell, as well as methods of using the variants, in particular within the field of animal feed and detergents. The invention furthermore relates to methods of generating and preparing protease variants of amended properties.
    Type: Application
    Filed: May 23, 2014
    Publication date: September 11, 2014
    Applicant: Novozymes A/S
    Inventors: Leonardo De Maria, Carsten Andersen, Lars Lehmann Hyllling Christensen, Soren Flensted Lassen, Peter Rahbek Ostergaard
  • Publication number: 20140227738
    Abstract: The present invention relates to isolated polypeptides having protease activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: September 21, 2012
    Publication date: August 14, 2014
    Applicant: Novozymes A/S
    Inventors: Jeppe Wegener Tams, Tine Hoff, Morten Gjermansen, Peter Rahbek Oestergaard, Robert Piotr Olinski, Katrine Pontoppidan, Carsten Sjoeholm
  • Patent number: 8795965
    Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: August 5, 2014
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventor: Feng Zhang
  • Patent number: RE45074
    Abstract: The present invention provides a method of pretreating a sample containing a glycated amine as an analyte, thereby enabling highly reliable measurement of a glycated amine. A glycated amino acid in the sample is degraded by causing a fructosyl amino acid oxidase (FAOD) to act thereon, and thereafter, a FAOD further is caused to act on the glycated amine as the analyte in the sample to cause a redox reaction. The amount of the glycated amine is determined by measuring the redox reaction. The substrate specificity of the FAOD caused to act on the glycated amino acid may be either the same as or different from that of the FAOD caused to act on the glycated amine. When using the same FAOD, a FAOD is caused to act on the glycated amino acid to degrade it, and thereafter, the sample is treated with a protease to inactivate the FAOD and also to degrade the glycated amine.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: August 12, 2014
    Assignee: ARKRAY, Inc.
    Inventors: Satoshi Yonehara, Tsuguki Komori